Google canceled publication of chest x-ray dataset due to privacy concerns

Google was hoping to release a massive dataset of chest x-rays to the public in 2017, but had to cancel at the last minute after receiving an urgent call from the National Institutes of Health (NIH).   

After reviewing various emails and conducting an interview with an anonymous source close to the incident, the Washington Post reported on the close call Nov. 15. According to the report, Google’s goal was to release a dataset of more than 100,000 chest x-ray images before an AI conference in Honolulu, Hawaii. NIH originally shared the images with Google, but then realized later some personal information had not been successfully scrubbed from images.

According to the Washington Post, the “fumbled project with NIH highlights potential pitfalls of Google’s ambitions with sensitive health data.” Google made headlines this month after details of its relationship with the Ascension health system were made public.

“We take great care to protect patient data and ensure that personal information remains private and secure,” Google spokesman Michael Moeschler said, as quoted by the Washington Post. “Out of an abundance of caution, and in the interest of protecting personal privacy, we elected to not host the NIH dataset. We deleted all images from our internal systems and did not pursue further work with NIH.”

Click below to read the full story:

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.